B · Normal
[Merck’s PD-1 inhibitor pembrolizumab injection (subcutaneous injection) approved in China] On September 29, Merck announced that the subcutaneous injection form of its PD-1 inhibitor pembrolizumab injection has been approved by the China National Medical Products Administration (NMPA), covering 19 solid tumor indications, becoming the first and currently the only PD-1 inhibitor approved for subcutaneous injection in China.
monoclonal antibody 🕐 2026-09-29 16:32
#monoclonal antibody #Pharmaceutical business #medicine
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Shanghai RAAS responded to the acquisition of a CDMO factory: intending to supp 09-29 13:56 On September 29th, Hengrui Pharmaceutical's H shares rose by more than 5%. The c 09-29 13:03 On September 28, the U.S. Food and Drug Administration (FDA) approved AbbVie’s J 09-28 20:01 [National Medical Insurance Administration: The continued procurement of oral me 09-28 17:20 [Hansoh Pharmaceutical responded to the withdrawal of the EU approval for Ametin 09-27 21:21 September 24th: Kobayashi Pharmaceutical is negotiating a US$3.2 billion privati 09-24 16:50

Comments

0/500
Captcha (click to refresh)
No comments yet